New research indicates that patients who stop using blockbuster weight-loss injections like Mounjaro or Wegovy can put back on lost weight much more quickly than those who end traditional lifestyle regimens.
Published data in a leading health publication demonstrates that while obese people frequently drop a large proportion of their body weight while on the medication, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation.
"People purchasing these drugs must be aware of the risk of fast rebound weight gain when the medication concludes," stated lead investigator Dr. Susan Jebb.
Such speed of regain means a reversion to starting weight in about a year and a half.
Comparing Therapies
The research, which reviewed 37 of studies involving over 9,000 of patients, compared the effects of GLP-1 agonists with older methods.
Researchers note that individuals who lose weight through lifestyle changes alone generally experience a less rapid weight regain—perhaps 0.1 kg a month—post-intervention.
Understanding the Rapid Rebound
Doctors suggest the way of the jabs accounts for the heightened regain.
The injections imitate a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Artificially providing the hormone concentrations far above than the body's typical production could lead to the system to generate a reduced amount of its endogenous GLP-1, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this GLP-1 'fix' means hunger is uncontrolled, making binge eating much more probable."
An Ongoing Disease?
The NHS recommend the jabs for people with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
Many experts argue that, given the likelihood of relapse, the therapy should be considered life-long.
This view is reinforced by drug manufacturers, who say that the results "emphasize the persistent nature of obesity," similar to managing diseases like diabetes.
Patient Testimonies
Users who have discontinued the medication report a sudden resurgence of appetite.
"It felt as if a trigger that goes on and you're instantly starving," said an individual.
This challenge is exacerbated if individuals have not developed permanent dietary or behavioural modifications during treatment.
Growing Adoption
Survey data suggest that millions of adults in the UK have used weight-loss jabs in the last 12 months, with demand continuing to grow.
- Adoption is greater among females than men.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion obtain the drugs through private healthcare rather than public health services.
Finally, clinicians stress that while GLP-1 drugs are effective agents for weight loss, they are not a standalone fix and lasting health benefits hinges on ongoing lifestyle support.